

# Gemini Stock Analysis Report

---

Based on the detailed analysis of the attached 23-page report for **AUROPHARMA.NS**, here is the positional trading assessment.

## Step 1: Audit the Data

- **Data Present:**
    - **Price Structure:** Daily (3-year), Weekly, and Intraday (15-min) charts.
    - **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend, MACD.
    - **Oscillators:** RSI, Bollinger Bands.
    - **Fundamental Data:** Revenue/Net Income growth trends (Long-term & Quarterly), Valuation metrics.
    - **Relative Strength:** Comparison against Benchmark (^CNXPHARMA).
    - **Volume Analysis:** Distribution days, Buying/Selling exhaustion signals.
    - **Forecasts:** Analyst estimates and price targets.
  - **Data Missing:**
    - Specific institutional holding changes (FII/DII data) are not explicitly detailed in the text summaries, though implied by "Trendlyne" snapshots.
  - **Confidence Level: High.** The report provides a comprehensive technical and fundamental view, including multi-timeframe analysis and specific signal dates, allowing for a precise evaluation.
- 

## Step 2: Analyze the Setup

- **Price Structure & Trend:**
  - **Status: Bearish Breakdown.**
  - The stock (INR 1132.50) is trading below all key Exponential Moving Averages (20 EMA @ 1173, 50 EMA @ 1178, and critically, the 200 EMA @ 1160).
  - The "Supertrend" is in a confirmed **Sell** signal since Jan 13, 2026.
  - The stock recently failed a volatility squeeze, breaking downwards (Page 15), which typically indicates momentum is accelerating to the downside.
- **Momentum & Oscillators:**
  - **MACD: Bearish.** The histogram is negative, and momentum is described as "Weakening."
  - **RSI:** At 37.29, it is weak but not yet oversold (typically <30). This suggests there is still room for further downside before a mean-reversion bounce occurs.
  - **Relative Strength:** The stock is classified as a "Weakening Leader" with an RS Score of 51.3/100, indicating it is severely underperforming the broader sector.
- **Fundamentals & Valuation:**
  - Short-term fundamentals are deteriorating, with recent Quarter-over-Quarter Revenue down -7.03% and Net Income down -8.71%.
  - The valuation check (Page 22) marks the stock as "Overvalued" relative to historicals.

**Conclusion on Setup:** The confluence of indicators is **negative**. The stock has lost its long-term support (200 EMA) and lacks a base formation. Trying to enter now would be fighting the prevailing trend ("catching a falling knife").

---

## Step 3: Formulate the Recommendation

**Direct Recommendation: NO, do not enter this stock now.**

The setup is currently invalid for a positional long trade because the price is below the 200-day EMA and the

# Gemini Stock Analysis Report

---

sector Relative Strength is deteriorating.

However, since you are looking for intermediate-term setups, we can set a "trap" for a potential reversal if institutional buyers step in to reclaim the trend.

## Conditional Plan (Watchlist Strategy):

- **Condition to Buy:** The stock must prove it has stabilized by reclaiming the confluence of resistance levels (The 200 EMA and 50 EMA). A daily **Close above INR 1,185** is required to confirm the trend has shifted back to Neutral/**Bullish**.
- **Entry Price:** **INR 1,185 - INR 1,190** (Only on a closing basis).
- **Stop Loss:** **INR 1,110** (Approximately 6-7% risk. This places the stop below the recent swing lows/psychological support).
- **Take Profit:** **INR 1,308** (This aligns with the analyst price target identified on Page 22 and structural resistance from late 2025).

**Risk Note:** Until the price reclaims INR 1,160 (200 EMA), the path of least resistance remains lower. Monitor for a potential "oversold bounce" if RSI hits 30, but do not mistake that for a trend reversal.

## News & Analyst Targets

**Date:** January 25, 2026 **Subject:** Stock Research Report: Aurobindo Pharma (AUROPHARMA)

As an equity research analyst, I have compiled the latest developments, analyst ratings, and market intelligence for **Aurobindo Pharma (AUROPHARMA)** for the week ending January 25, 2026.

### 1) Latest News for AUROPHARMA (Week of Jan 19-25, 2026)

- **New Subsidiary in Philippines (Jan 23, 2026):** Aurobindo Pharma has officially incorporated a new step-down subsidiary named "**Aurobindo Pharma Philippines, Inc.**" on January 23, 2026. This entity is a wholly-owned subsidiary intended to strengthen the company's footprint in the Southeast Asian market.
- **CLSA Upgrade to "Outperform" (Jan 23, 2026):** Global brokerage firm CLSA upgraded the stock from *Hold* to *Outperform*. They cited the recent ~20% correction in the stock price as a buying opportunity, although they lowered their target price to account for revised earnings multiples.
- **Technical Weakness & Sell Signal:** The stock has been under pressure this week, triggering a technical "Sell" signal (MACD crossover) around January 23. The share price moved down ~1.1% late in the week, closing near INR 1,132-INR 1,145 levels, driven by broader sector weakness.
- **Upcoming Q3 Earnings:** The company has closed its trading window in preparation for its Q3 FY26 financial results. The earnings release is tentatively expected around **February 4, 2026**.

### 2) Brokerage Upgrades & Downgrades

- **Upgrade (CLSA): UPGRADE to Outperform** (from Hold).
  - *Rationale:* Valuation has become attractive following the steep correction in the stock price over the last three weeks.
  - *Note:* Despite the upgrade in rating, the price target was cut to **INR 1,400** (from INR 1,540) to reflect a lower target PE multiple (19x vs 20x).
- **Maintained Ratings:** Most domestic brokerages have maintained their ratings pending the Q3 results, with a general consensus leaning towards "Buy" or "Add" for the long term, despite near-term headwinds.

### 3) Other News Impacting AUROPHARMA

# Gemini Stock Analysis Report

- **US FDA Regulatory Environment:** While there were no *new* adverse observations issued specifically this week (Jan 19-25), the stock remains sensitive to regulatory news. The market is still digesting the **Form 483 observations** issued to its **Unit-IV (APL Healthcare)** in mid-December 2025 and **Unit-XII** earlier in late 2025. The company has stated these are procedural, but any delays in clearance could impact US revenue sentiment.
- **Sector-Wide Pricing Pressure:** The broader Indian pharma sector is facing headwinds from potential US policy changes and generic pricing pressure. This "sector rotation" away from pharma has contributed to Aurobindo's recent underperformance relative to the Nifty 50.
- **Acquisition Integration:** The company effective Jan 1, 2026, completed the acquisition of the non-oncology formulations business of **Khandelwal Laboratories**. Investors are monitoring how quickly this domestic portfolio (focused on pain management and antibiotics) will be accretive to earnings.

## 4) Analyst Targets & Consensus

Below is the summary of the latest available price targets from major brokerage houses as of January 25, 2026.

Brokerage Firm	Rating / View	Target Price (INR)	Comments
HDFC Securities	BUY	1,755	Remains bullish on long-term US generic pipeline.
Axis Securities	OVERWEIGHT	1,500	Positive on specialty margin expansion.
CLSA	OUTPERFORM	1,400	Revised Down from 1,540 on Jan 23. Upgraded rating on valuation comfort.
Sharekhan	BUY	1,600	Focus on reduced debt and biosimilar traction.
ICICI Securities	ADD	1,330	Conservative stance pending FDA clearances.
Consensus Mean	BUY	~1,515	Average upside potential of ~30% from current levels.

**Disclaimer:** This research is for informational purposes only. Please consult your financial advisor before making any investment decisions.


# Stock Detailed Analysis Report

**AUROPHARMA.NS**

Current Price: ₹1132.50

Generated: 2026-01-24 18:28

# AUROPHARMA.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

# AUROPHARMA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	51.3/100
:	

## == RS RATIOS ==:

1M RS:	<b>0.981 [Neutral]</b>
3M RS:	<b>1.082 [Leader]</b>
6M RS:	<b>1.055 [Leader]</b>
1Y RS:	<b>0.957 [Neutral]</b>
:	

## == TURNAROUND ANALYSIS ==:


Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::


✗ Emerging RS:	<b>Not accelerating</b>
✓ Medium-term Lagging:	1Y=0.957 ( $\leq 1.0$ )
✗ Performance Improving:	<b>Not improving</b>

Relative Strength Analysis: AUOPHARMA.NS vs ^CNXPHARMA  
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline





## AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1173.58
EMA 50:	1178.08
EMA 200:	1160.48
Trend Status:	<b>Short-term Downtrend</b>
Golden Cross Date:	2025-11-25 00:00:00+05:30
Golden Cross Price:	1208.00


AUROPHARMA.NS EMA Crossover Analysis



## AUROPHARMA.NS - Bollinger Bands Summary

<b>Current Price:</b>	1132.50
<b>Upper Band:</b>	1245.78
<b>Middle Band (SMA 20):</b>	1183.25
<b>Lower Band:</b>	1120.73
<b>%B:</b>	0.0941
<b>Band Width:</b>	0.1057
<b>Status:</b>	Lower Half
<b>Signal:</b>	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



## AUROPHARMA.NS - Supertrend Summary

Status:	<b>DOWNTREND (Sell)</b>
Supertrend Value:	1227.39
Signal Identified On:	2026-01-13

Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## AUROPHARMA.NS - MACD Summary

MACD Line:	-15.68
Signal Line:	-7.92
Histogram:	-7.77
Trend:	<b>Bearish</b>
Momentum:	<b>Weakening</b>
Signal:	None

AUROPHARMA.NS Price



AUROPHARMA.NS MACD (12, 26, 9)








## AUROPHARMA.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.1057
<b>ATR:</b>	30.5786
<b>Total Signals:</b>	35
<b>Signal 1:</b>	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10)
<b>Signal 2:</b>	BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70)
<b>Signal 3:</b>	BB Squeeze at 2026-01-12 00:00:00+05:30 (Price: 1172.90)
<b>Signal 4:</b>	BB Squeeze at 2026-01-13 00:00:00+05:30 (Price: 1167.70)
<b>Signal 5:</b>	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1180.10)


# AUROPHARMA.NS - Volatility Squeeze Analysis



# AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	37.29
Current Volume:	511867
Volume MA 20:	871244
Bullish Divergences:	1
Bearish Divergences:	2
Bullish Div 1:	Date: 2025-02-03 00:00:00+05:30, Price: 1121.19
Bearish Div 1:	Date: 2024-08-30 00:00:00+05:30, Price: 1563.53
Bearish Div 2:	Date: 2025-10-13 00:00:00+05:30, Price: 1136.80

# AUROPHARMA.NS RSI-Volume Divergence Analysis



# AUROPHARMA.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

Status:

**32 Signals Detected**

:

**2025-12-31 [-]:**

Distribution Day

**2026-01-07 [-]:**

Climax Volume (Churning)

**2026-01-09 [-]:**

Distribution Day



**2026-01-16 [-]:**

Distribution Day

**2026-01-21 [+]:**

**Selling Exhaustion (Bullish Div)**

# AUROPHARMA.NS - Volume Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1122.17	1132.5	2025-11-10
1 Day	DOWNTREND (Sell)	1227.39	1132.5	2026-01-13
15 Min	DOWNTREND (Sell)	1138.03	1128.5	2026-01-23

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	Bearish Crossover (Sell)
1 Day	Bearish	Weakening	No Signal
15 Min	Bearish	Weakening	No Signal

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)



AUROPHARMA.NS - 1 Day (Candlestick + EMAs)




AUROPHARMA.NS - 15 Min (Candlestick + EMAs)





## Trendlyne Snapshot - AUROPHARMA\_main



Aurobindo Pharma Key Metrics

ROE Ann. %10.7

Below Industry Median

Broker Average Target1,349.22

19.14% upside

Market Capitalization65,775.8

High in industry

Price to Book1.7

Below Industry Median

DVM

Key Metrics

Price Chart

Forecaster

Financials

Technicals

Shareholding

Deals

Documents

Corporate actions

Company Profile

## Trendlyne Snapshot - AUROPHARMA\_forecaster

Markets

STARFOLIO

Alerts

F&O

MF

Reports

Screeners

Subscribe

Superstars

Portfolio

Watchlist

Insider Trades

Results

Data Downloader

More

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

In 5 Starfolio Baskets

1132.50

-12.80 (-1.12%)

522.7K

NSE+BSE Volume

NSE 23 Jan, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

### Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1308, revenue growth forecast of 4.8%, and profit growth estimate of 4.4% for FY26, based on top 28 analyst calls.

## Aurobindo Pharma FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#)